logo

Zosano Pharma Corporation (ZSAN)



Trade ZSAN now with
  Date
  Headline
1/16/2019 8:34:20 AM Zosano Appoints Linda Grais To Board
10/16/2018 8:31:41 AM Zosano Pharma Appoints Greg Kitchener CFO
10/3/2018 8:35:25 AM Zosano Pharma Announces Manufacturing And Supply Agreement For M207
9/26/2018 8:31:25 AM Zosano Pharma Enters Into Capital Equipment Lease Agreement With Trinity Capital Investment
9/6/2018 8:38:00 AM Zosano Pharma To Present Phase 3 Safety Study Update For ADAM Technology In Delivery Of Zolmitriptan
7/17/2018 8:37:45 AM Zosano Says Positive Data From Evaluation Of Pharmacokinetics And Skin Tolerability Study For ADAM Technology
5/23/2018 8:36:40 AM Zosano Reports Publication Of Most Bothersome Symptom Data From ZOTRIP Pivotal Study In Headache
5/22/2018 8:35:44 AM Zosano Appoints Steven Elms To Board Of Directors
5/15/2018 4:08:02 PM Zosano Pharma Q1 Loss/share $4.16 Vs. Loss $6.89 Year Ago
4/3/2018 4:17:29 PM Zosano Announces Closing Of Public Offering Of Common Stock
3/29/2018 9:09:03 AM Zosano Pharma Announces Pricing Of Underwritten Public Offering Of 10 Mln Shares At $5.00/shr
3/16/2018 8:32:45 AM Zosano Reaches Enrollment Milestone In M207-ADAM Long-term Safety Study
3/12/2018 8:47:58 AM Zosano Pharma Q4 Loss Per Share $3.80 Vs Loss $9.23 Last Year
3/2/2018 8:33:51 AM Zosano Pharma Reports Issuance Of New U.S. Patent Covering M207 As An Acute Treatment For Migraine